To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
Trial · NCT01496313
Adverse events936
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 936
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Randomized Period: Vandetanib 150 mg | 0 | 40 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Randomized Period: Vandetanib 300 mg | 2 | 41 | 2 |
| other | Anaemia | Blood and lymphatic system disorders | Open-label Period: Vandetanib 100 mg | 0 | 5 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Open-label Period: Vandetanib 150 mg | 0 | 9 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Open-label Period: Vandetanib 200 mg | 1 | 8 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | Open-label Period: Vandetanib 300 mg | 0 | 39 | 0 |
| other | Sinus Tachycardia | Cardiac disorders | Randomized Period: Vandetanib 150 mg | 0 | 40 | 0 |
| other | Sinus Tachycardia | Cardiac disorders | Randomized Period: Vandetanib 300 mg | 1 | 41 | 2 |
| other | Sinus Tachycardia | Cardiac disorders | Open-label Period: Vandetanib 100 mg | 0 | 5 | 0 |
| other | Sinus Tachycardia | Cardiac disorders | Open-label Period: Vandetanib 150 mg | 0 | 9 | 0 |
| other | Sinus Tachycardia | Cardiac disorders | Open-label Period: Vandetanib 200 mg | 1 | 8 | 1 |
| other | Sinus Tachycardia | Cardiac disorders | Open-label Period: Vandetanib 300 mg | 0 | 39 | 0 |
| other | Vertigo | Ear and labyrinth disorders | Randomized Period: Vandetanib 150 mg | 0 | 40 | 0 |
| other | Vertigo | Ear and labyrinth disorders | Randomized Period: Vandetanib 300 mg | 0 | 41 | 0 |
| other | Vertigo | Ear and labyrinth disorders | Open-label Period: Vandetanib 100 mg | 0 | 5 | 0 |
| other | Vertigo | Ear and labyrinth disorders | Open-label Period: Vandetanib 150 mg | 0 | 9 | 0 |
| other | Vertigo | Ear and labyrinth disorders | Open-label Period: Vandetanib 200 mg | 1 | 8 | 1 |
| other | Vertigo | Ear and labyrinth disorders | Open-label Period: Vandetanib 300 mg | 0 | 39 | 0 |
| other | Hypothyroidism | Endocrine disorders | Randomized Period: Vandetanib 150 mg | 3 | 40 | 3 |
| other | Hypothyroidism | Endocrine disorders | Randomized Period: Vandetanib 300 mg | 5 | 41 | 6 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01496313/events